Loading clinical trials...
Loading clinical trials...
Clinical Pilot to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients With Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC) Treated With Erlotinib and Bevacizumab and to Associate Imaging Findings With Molecular Markers
Conditions
Interventions
Erlotinib, Bevacizumab
Fluoro-D-glucose
+2 more
Locations
1
Germany
Center for Integrated Oncology (CIO), University Hospital Cologne
Cologne, North Rhine-Westphalia, Germany
Start Date
January 1, 2010
Primary Completion Date
October 1, 2012
Completion Date
May 1, 2016
Last Updated
May 20, 2016
NCT06487078
NCT06461338
NCT04738487
NCT04990479
NCT03950674
NCT03770299
Lead Sponsor
University of Cologne
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions